Evenity vs Forteo
Side-by-side cost comparison based on Medicare Part D data
Evenity
Romosozumab
Manufactured by Amgen/UCB
Forteo
Teriparatide
Manufactured by Eli Lilly
Forteo costs 42% less per claim than Evenity ($1,337.00 vs $2,286.00). A generic version of Forteo is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Evenity | Forteo |
|---|---|---|
| Avg Cost Per Claim | $2,286.00 | $1,337.00 |
| Total Medicare Spending | $567.0M | $567.0M |
| Total Beneficiaries | 32,000 | 48,000 |
| Total Claims | 248,000 | 424,000 |
| Annual Cost/Patient | $17,719.00 | $11,813.00 |
| Year-over-Year Change | +28.4% | -18.4% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Amgen/UCB | Eli Lilly |
| Condition | Osteoporosis | Osteoporosis |
| Generic Name | Romosozumab | Teriparatide |
Evenity vs Forteo: What the Data Shows
Evenity (Romosozumab) and Forteo (Teriparatide) are both used to treat osteoporosis. Based on Medicare Part D data, Forteo costs $1,337.00 per claim, which is 42% less than Evenity at $2,286.00 per claim.
Medicare spent $567.0M on Evenity and $567.0M on Forteo. In terms of patient reach, Forteo serves more beneficiaries (48,000 vs 32,000).
Year-over-year spending changed +28.4% for Evenity and -18.4% for Forteo. Evenity saw significant spending growth, suggesting increased utilization or price increases.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Forteo is cheaper at $1,337.00 per claim, compared to $2,286.00 for Evenity. That makes Forteo about 42% less expensive per claim based on Medicare Part D data.
Yes, both Evenity and Forteo are used to treat osteoporosis. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Romosozumab and generic Teriparatide can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $567.0M on Evenity covering 32,000 beneficiaries, and $567.0M on Forteo covering 48,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.